title: Feasibility of cell-free circulating tumor DNA testing for lung cancer.
abstract: Tumor tissue genotyping is used routinely for lung cancer to identify specific targetable oncogenic alterations, including EGFR mutations and ALK rearrangements. However, tumor tissue from a single biopsy is often insufficient for molecular testing, may offer a limited evaluation because of tumor heterogeneity and can be difficult to obtain. Cell-free circulating tumor DNA has been widely investigated as a potential surrogate for tissue biopsy for noninvasive assessment of tumor-related genomic alterations. New techniques have improved EGFR mutations detection in ctDNA, thus supporting the use of this liquid biopsy for predicting response to EGFR tyrosine kinase inhibitors (TKIs) and monitoring the emergence of resistance. The serial evaluation of ctDNA during treatment is feasible and can be used to track tumor changes in real time and for a wide range of clinically useful applications.
authors.affiliation: Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
authors.forename: Mariacarmela
authors.initials: M
authors.lastname: Santarpia
authors.affiliation: Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain.
authors.forename: Niki
authors.initials: N
authors.lastname: Karachaliou
authors.affiliation: Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: González-Cao
authors.affiliation: Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Altavilla
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.|Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Giovannetti
authors.affiliation: Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain.|Pangaea Biotech, Barcelona, Spain.|Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.|Germans Trias i Pujol Health Sciences Institute & Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.|Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology*; D004273:DNA, Neoplasm / Q000097:blood*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology*; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases
keywords: EGFR mutations; circulating cell-free DNA (cfDNA); non-small-cell lung cancer